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Abstract: A synthetic tripodal-based thiourea receptor (PNTTU) was used to  
explore the receptor/ligand binding affinity using CTB cells. The human extravillous  
CTB cells (Sw.71) used in this study were derived from first trimester chorionic villus 
tissue. The cell proliferation, migration and angiogenic factors were evaluated in  
PNTTU-treated CTB cells. The PNTTU inhibited the CTBs proliferation and migration.  
The soluble fms-like tyrosine kinase-1 (sFlt-1) secretion was increased while  
vascular endothelial growth factor (VEGF) was decreased in the culture media of  
CTB cells treated with ≥1 nM PNTTU. The angiotensin II receptor type 2 (AT2) expression 
was significantly upregulated in ≥1 nM PNTTU-treated CTB cells in compared to basal; 
however, the angiotensin II receptor, type 1 (AT1) and vascular endothelial growth factor 
receptor 1 (VEGFR-1) expression was downregulated. The anti-proliferative and  
anti-angiogenic effect of this compound on CTB cells are similar to the effect of CTSs.  
The receptor/ligand affinity of PNTTU on CTBs provides us the clue to design  
OPEN ACCESS
Int. J. Environ. Res. Public Health 2014, 11 7457 
 
 
a potent inhibitor to prevent the CTS-induced impairment of CTB cells. 




Preeclampsia (preE) is a hypertensive disorder unique to pregnancy with multiple etiologies that 
affects about 3 to 10 percent of pregnant women [1,2]. In a rat model of preE, it has been shown that 
urinary marinobufagenin (MBG) levels are elevated prior to the development of hypertension 
indicating that it may play a key role in the pathogenesis of preE [3]. Cardiotonic steroids (CTSs),  
such as MBG, cinobufotalin (CINO), and ouabain (OUB), are endogenous inhibitors of Na+/K+ 
ATPase [4–7]. It has been demonstrated that CTSs impair cytotrophoblast (CTB) cell function [8,9]. 
The receptor/receptors of CTSs on CTBs has/have not been fully understood. We have studied the 
effect of CTSs on pregnancy using CTB cells in order to determine their role in preE [8,9].  
The CTSs inhibited CTB proliferation, migration, invasion, and ERK1/2 phosphorylation and they 
activated Jnk1/2 phosphorylation, p38 phosphorylation, and apoptosis evaluated by caspase 3/7 and 
annexin-five staining [8,9]. The CTSs also arrested cell cycle progression without causing a cytotoxic 
effect on the cells [8,9]. We have demonstrated that CTS induced impairment of CTBs and endothelial 
cells function occurs via the modulation of MAPK signaling, cell cycle arrest, and the activation of 
apoptosis [10–12].  
Urea- or thiourea-based synthetic receptors are known to interact with an anion under neutral 
conditions [13–16]. Recently, it has been reported that such compounds have the potential to act as 
anticancer agents through transmembrane transport mechanisms of anions in vitro [17]. In this study, 
we have been interested in using a thiourea-based molecule, PNTTU (para-nitro tripodal thiourea, 
Figure 1) as a cell surface receptor for CTSs. The basic feature of PNTTU is that it contains three 
functional groups as active thiourea (HN(C=S)NH) groups in the attached three arms forming  
a triopodal cavity which was previously shown to bind anions [18–20]. The presence of three  
p-nitro groups as electron withdrawing substituents enhances the acidity of the attached NH groups, 
thereby increasing the overall activity of the ligand. This hypothesis was supported by a calculation of 
the electrostatic potential surfaces of a related compound at the M06-2X/6-31G(d,p) level of theory, 
showing the most positive potential on the NH groups [21]. In addition, the conformational flexibility 
with six H-donor groups may allow the ligand to interact with active sites of a cell.  
CTSs have a specific binding site on the extracellular loops (TM1–TM2, TM5–TM6, and TM7–TM8) 
of the α subunit of Na+/K+ ATPase [22]. The sensitivity of the sodium pump to CTSs is controlled by 
multiple mechanisms in addition to the tissue specificity of α and β isoform distributions [22].  
CTSs are stimulated to promote natriuresis via inhibition of the Na+/K+ pump in renal tubules and are 
likely to exhibit a prohypertensive action via inhibition of the Na+/K+ pump in vascular  
sarcolemma [4,23]. Recently, several research teams proposed that CTSs are also involved in  
Na+-independent signaling. This hypothesis was based on data showing that at lower concentrations 
CTSs augment cell proliferation [24,25], DNA synthesis [24], mitogen-activated protein kinase 
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activity [5,24,26], and the production of reactive oxygen species [6,27] without significant inhibition 
of the Na+/K+ pump and elevation of [Na+]i. Another possible approach to interfere with the effect of 
CTSs is the inhibition of the Na+/Ca2+ exchanger, NCX1 [27]. CTSs inhibit Na+/K+ ATPase in 
vascular smooth muscle cells; the elevation of local Na+ facilitates Ca2+ entry through NCX1, resulting 
in vasoconstriction [7]. There are two types of CTSs, cardenolides (OUB) and bufadienolides  
(MBG and CINO). Cardenolides have a five-member lactone ring whereas bufadienolides have a  
six-member lactone ring. The cardenolides have been determined to have a predilection for the α2 and 
α3 isoforms of Na+/K+ ATPase, whereas the bufodienolides act primarily on the α1 isoform [28]. 
Recent studies [9,10,29] demonstrated that CTSs induced the apoptotic signaling and caused cell cycle 
arrest in CTBs. These findings indicate that CTSs are not only interacting through the Na+/K+ ATPase, 
they also enter into the cells via other receptor/receptors and cause the intercellular signaling.  
The receptor/receptors of CTSs on CTB cell surface has/have not been yet been studied. The aim of 
the study was to investigate the effects of PNTTU on CTB cell proliferation and expression of some 
markers of angiogenesis and angiotensin II effect. 












2. Experimental Section  
2.1. General Information 
The CTB cell culture media DMEM/F-12 was purchased from Invitrogen, Grand Island, NY, USA 
and cell were incubated in an Isotemp CO2 Incubator, Fisher, Waltham, MA, USA. RPMI Media and 
gels were purchased from Invitrogen, Grand Island, NY, USA. Cell viability and cell proliferation 
assay kits were purchased from Promega, Madison, WI, USA. Cell migration assay kit was purchased 
from Cell Biolabs, San Diego, CA, USA. BCA protein assay kit and chemiluminescent substrate were 
from Pierce, Rockford, IL, USA. The Qunatikine ELISA was purchased from R&D Systems, 
Minneapolis, MN, USA. The nitrocellulose membranes were from Bio-Rad, Hercules, CA, USA.  
The primary and secondary antibodies were purchased from Santa Cruz Biotechnology, Paso Robles, 
CA, USA; Abcam, Cambridge, MA, USA and Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA. Absorbance was measured on a plate reader, SPECTRAmax 340PC384, Molecular Devices, 
Sunnyvale, CA, USA. The fluorescence was measured at on a fluorescence plate reader,  
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CytoFluor Series 4000 Fluorescence Multi-Well Plate Reader, Applied Biosystems, Grand Island,  
NY, USA. The chemiluminence detection system was used LAS-3000 Imaging System,  
Fuji Photo Film Co., Ltd., Minato-ku, Tokyo, Japan. 
2.2. Synthesis of PNTTU 
To a solution of 4-nitrophenyl isothiocyanate (1.843 g, 10.23 mmol) in THF (50 mL) was added a 
solution of tris(2-aminoethyl) amine (520 µL, 3.41 mmol) in THF (50 mL) dropwise at room 
temperature under constant stirring. The reaction mixture was refluxed at 75 °C for 36 h.  
Then the mixture was cooled to room temperature and was poured over hexane (30–40 mL), yielding a 
yellow precipitate. Yield: 2.1 g, 89%. 1H-NMR (500 MHz, DMSO-d6, TSP): δ 10.17  
(s, 3H, Ar-NH), 8.17 (s, 3H, CH2NH), 8.13 (d, J = 9.20 Hz, 6H, ArH), 7.78 (d, J = 9.15 Hz, 6H, ArH), 
3.66 (t, J = 6.10 Hz, 6H, NHCH2), 2.81 (t, J = 6.72 Hz, 6H, NCH2). 13C-NMR (125 MHz, DMSO-d6,): 
δ 179.82 (C = S), 146.14 (Ar-C), 141.65 (ArC-NO2), 124.52 (Ar-CH), 120.25 (Ar-CH), 51.56 (NHCH2), 
41.83 (NCH2). M.P 196 °C. ESI-MS: m/z (%) 686.9 (MH+). Anal. Calcd. For C27H30N10O6S3:  
C, 47.22; H, 4.40; N, 20.39. Found: C, 47.17; H, 4.36; N, 20.02. IR (KBr): νN-H 3,445 and 3,276 cm−1; 
νC=S 1,107 cm−1; νN=O 1,511 and 1,332 cm−1. 
2.3. Cell Culture 
The human extravillous cytotrophoblast cell line Sw.71 utilized in these studies was derived from 
first trimester chorionic villus tissue and was kindly provided by Gil G. Mor at the School of Medicine, 
Yale University (New Haven, CT, USA). These cells are well characterized and share many 
characteristics with isolated primary cells, including the expression of cytokeratin-7, HLA class I antigen, 
HLA-G, BC-1, human chorionic gonadotropin, and human placental lactogen [30–33].  
Sw.71 cells were cultured in DMEM/F-12 (Invitrogen, Grand Island, NY, USA) supplemented with 
10% fetal bovine serum, 10 mM Hepes, 0.1 mM MEM non-essential amino acids, 1 mM sodium 
pyruvate and 100 U/mL penicillin/streptomycin. Cells were incubated at 37°C, 5% CO2,  
and 99% humidity (Isotemp CO2 Incubator, Fisher, Waltham, MA, USA).  
2.4. Effect of PNTTU on CTB Cells Function 
Cell viability was measured using a CellTiter Assay (Promega, Madison, WI, US) and treatments of  
0, 0.1, 1, 10, and 100 nM PNTTU for 48 h. After the CellTiter-Blue reagent was added to the cells,  
the absorbance at 520 nm was measured on a plate reader (SPECTRAmax 340PC384, Molecular 
Devices, Sunnyvale, CA, USA). Cell proliferation was measured using a CellTiter Assay (Promega, 
Madison, WI, USA), which is a colorimetric method for determining the number of viable cells.  
Cells were treated with 0, 0.1, 1, 10, and 100 nM PNTTU for 48 h. After CellTiter 96 was added to  
the cells, the absorbance at 490 nm was measured on a plate reader (SPECTRAmax 340PC384, 
Molecular Devices, Sunnyvale, CA, USA). Cell migration was measured using a CytoSelect Assay 
(Cell Biolabs, San Diego, CA, USA) with treatments of 0, 0.1, 1, 10, and 100 nM PNTTU for 48 h.  
After the CyQuant GR Dye solution was added to the cells, fluorescence was measured at  
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480 nm/520 nm on a fluorescence plate reader (CytoFluor Series 4000 Fluorescence Multi-Well  
Plate Reader, Applied Biosystems, Grand Island, NY, USA).  
2.5. ELISA for Angiogenic and Anti-angiogenic Factors 
Cells were treated with RPMI Media (Invitrogen) containing 0.1, 1, 10, or 100 nM PNTTU for 48 h. 
The supernatants of PNTTU treated cells were analyzed using a Qunatikine ELISA (R&D Systems, 
Minneapolis, MN USA) for concentrations of sVEGF R1/Flt-1 (sFlt-1) and VEGF165. These assays 
employ the quantitative sandwich enzyme immunoassay technique. Monoclonal antibodies specific for 
sFlt-1 and VEGF165 were pre-coated onto the microplate. Standards and samples are pipetted into the 
wells and any sFlt-1 and VEGF165 present is bound by the immobilized antibody. After washing away 
any unbound substances, an enzyme-linked polyclonal antibody specific for either sFlt-1 or VEGF165 
is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent,  
a substrate solution is added to the wells and a color develops in proportion to the amount of sFlt-1  
or VEGF bound in the initial step. The color development is stopped and the intensity of the color is 
measured using a plate reader (SPECTRAmax 340PC384, Molecular Devices). 
2.6. Western Blots for VEGFR-1, AT1, and AT2 Receptors 
Cells were treated with RPMI Media (Invitrogen) containing 0.1, 1, 10, or 100 nM PNTTU for 48 
h. The cell lysates were utilized to measure VEGFR-1, AT1, and AT2 receptor expression. Protein 
concentrations of cell lysates were determined using a BCA Protein Assay Kit (Pierce, Rockford,  
IL, USA). An equal amount of protein of each sample was run on a NuPAGE Novex 4%–12%  
Bis-Tris Gel (Invitrogen) and transferred to 0.45 μm nitrocellulose membranes (Bio-Rad, Hercules, 
CA, USA). Membranes were blocked in 5% milk and incubated with VEGFR-1 (Invitrogen), AT1, 
(Santa Cruz Biotechnology, Paso Robles, CA, USA) and AT2 (Abcam, Cambridge, MA, USA) 
antibodies. After the addition of the corresponding secondary antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA), proteins were visualized with SuperSignal West Dura 
Chemiluminescent Substrate (Pierce) and a chemiluminence detection system (LAS-3000 Imaging 
System). Densitometry was measured using ImageJ (NIH) and normalized using β-actin. 
2.7. Statistical Methods 
Data are presented as mean ± SEM. Data from PNTTU-treated groups were compared to basal 
(DMSO)-treated groups using a one-way analysis of variance with Tukey’s post hoc test. A p value of 
less than 0.05 was considered significant. 
3. Results and Discussion 
3.1. Results 
3.1.1. PNTTU Inhibited the CTB Cells Function 
CTB cell proliferation was significantly inhibited (approximately 75%) by 1, 10, and 100 nM of 
PNTTU compared to basal (p < 0.05), while 0.1 nM PNTTU had no effect (Figure 2A). These results 
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suggest that PNTTU has an anti-proliferative effect on CTB cell function prior to their differentiation. 
The anti-proliferative capacity of PNTTU on the cells was not due to a cytotoxic effect of the 
compound, as evaluated by cell viability (Figure 2B). Cell migration was significantly (p < 0.05) 
inhibited (approximately 58%) by 1, 10, and 100 nM PNTTU when compared to basal,  
while 0.1 nM PNTTU had no effect (p > 0.05) (Figure 2C).  
Figure 2. CTB cells were treated with different concentrations of PNTTU and  
(A) Proliferation, (B) Cell Viability, and (C) Migration were measured. PNTTU 
significantly (* p < 0.05) downregulated the proliferation and migration in CTB cells and 
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(C) 
3.1.2. PNTTU Upregulated Anti-angiogenic Factor (sFlt-1) and Downregulated Angiogenic  
Factor (VEGF) 
The secretion of sFlt-1 was significantly increased in the culture media of CTB cells treated  
with ≥1 nM by PNTTU (Figure 3A), however, the secretion of VEGF was decreased in the culture 
media of CTB cells treated with ≥1 nM by PNTTU (Figure 3B). 
Figure 3. CTB cells were treated with different concentrations of PNTTU and the levels of 
(A) sFlt-1 and (B) VEGF were measured in the cell culture media by ELISA.  
PNTTU significantly (* p < 0.05) upregulated the secretion of sFlt-1 and downregulated 
the secretion of VEGF by CTB cells. The results are presented as the mean ± SEM  
(n = 6, four replicates each).  
 
(A) 
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(B) 
3.1.3. PNTTU Downregulated VEGFR-1 and AT1 Receptor Expression and Upregulated AT2  
Receptor Expression 
The VEGFR-1 (Figure 4A) and AT1  (Figure 4B) receptors expression was downregulated in ≥1 nM 
PNTTU treated CTB cells compared to basal, however, the AT2 receptor expression was significantly 
upregulated in ≥1 nM PNTTU treated CTB cells compared to basal (Figure 4C). 
Figure 4. CTB cells were treated with different concentrations of PNTTU and  
(A) VEGFR1, (B) AT1 receptor, and (C) AT2 receptors expression were measured in the 
cell lysates by western Blot. PNTTU significantly (* p < 0.05) downregulated  
the expression of VEGFR1 and AT1 receptors in CTB cells and upregulated the expression 
of AT2 receptor. The data are presented as mean ± SEM for four experiments.  
A blot from a representative experiment is shown in each of the figures. 
 
(A) 
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PNTTU has been shown to inhibit the proliferation and migration of CTB cells. The synthetic receptor 
is found to down-regulate angiogenic factor (VEGF) and up-regulate anti-angiogenic factor (sFlt-1). 
Furthermore, PNTTU has shown to upregulate AT2 receptor expression and downregulate VEGFR-1 
and AT1 receptor expression. All these effects of PNTTU are similar with our previous findings of 
CTSs on CTB cells [8–10,34]. Previous study suggested that the PNTTU has strong affinity for an 
anionic species [18–20] particularly for phosphate [19,20]. Therefore, it is suggested that the PNTTU 
possibly interacts with phosphate groups of Na+/K+ ATPase, as well as with carboxyl groups of 
membrane receptors. In the first trimester of pregnancy, the CTB cells of the extravillous trophoblast 
column migrate through and invade the decidualized endometrium attaching the placenta to the uterus. 
They then breach and subsequently line uterine blood vessels channeling maternal blood to the rest of 
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the placenta. Adequate CTB invasion sets into motion events that ultimately lead to the remodeling of 
the maternal vessels which is a crucial phase for proper placental establishment. This process of 
remodeling is essential for the fetus which needs increased maternal blood flow as the pregnancy 
progresses. Defects in CTB differentiation are often associated with preE. The amount of interstitial 
invasion is frequently reduced and the endovascular invasion is consistently rudimentary [35]. 
Consequently, there is a reduction in uteroplacental perfusion that leads to placental focal ischemia and 
hypoxia later in pregnancy [36]. 
Although the exact mechanism of preE continues to elude researchers and clinicians, several 
theories have been postulated. One theory looks at the roles of bufodeinolides, a subgroup of cardiac 
steroids (CTSs). The most studied of this group is, MBG, which has been shown to be elevated in both 
animal models and human subjects with preE in response to increased volume expansion [3,37–39]. 
Others have shown that MBG levels are elevated prior to the onset of hypertension and proteinuria 
implicating MBG as a factor in the pathogenesis of preE. MBG has also been shown to interfere with 
proliferation, migration and invasion of CTB cells showing its role in abnormal placentation seen in 
preE [3,8–10]. MBG- and ouabain-induced activation of Jnk, p38, and Src, activation of caspase 9 and 
3/7, positive annexin-V staining, and increased secretion of IL-6 in CTB cells suggest that these 
cardiotonic steroids increase apoptotic signaling and lead to apoptosis in CTB cells [9]. MBG was also 
shown to upregulate Jnk and p38 phosphorylation and activate apoptosis in rat lung microvascular 
endothelial (RLME) cells as confirmed by activation of caspases 3/7, 8, and 9 as well as Annexin-V 
staining [10]. A p38 inhibitor was shown to attenuate the activation of apoptosis by MBG in RLME 
cells [10]. MBG inhibited proliferation, increased monolayer permeability, decreased ERK1/2 
phosphorylation, activated Jnk, p38, and Src phosphorylation, increased the expression of caspase 3/7 
indicating the activation of apoptosis in human brain microvascular endothelial (HBME) cells [11]. 
Figure 5. Diagram showing the interactions of the thiourea functional groups in the 
synthetic receptor PNTTU with membrane receptors via residual carboxyl groups resulting 
in the decrease of signaling for proliferative and angiogenic profile. 
 
↑AT1 & VEGFR1 Receptor
Decreased Proliferation and Migration
Increased Anti-angiogenic Profile
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4. Conclusions  
We propose that the thiourea functional groups in PNTTU interact with membrane receptors 
possibly through residual carboxyl groups resulting in the decrease of signaling for proliferative and 
angiogenic profiles (Figure 5). The receptor/ligand binding affinity of PNTTU on CTB cells provides 
us to design an effective inhibitor to prevent the CTS-induced impairment of CTBs. Research work is 
undergoing with different synthetic receptors to identify the functional group that is responsible for 
CTBS dysfunction.  
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